Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia

References

• Sinclair R. Male pattern androgenetic alopecia. Br Med J. 1998;317:865–869.
   PubMed Web of Science ®Google Scholar
• Wang TL, Zhou C, Shen YW, et al. Prevalence of androgenetic alopecia in China: a community-based study in six cities. Br J Dermatol. 2010;162(4):843–847.
   PubMed Web of Science ®Google Scholar
• Gonzalez ME, Cantatore-Francis J, Orlow SJ. Androgenetic alopecia in the pediatric population: a retrospective review of 57 patients. Br J Dermatol. 2010;163(2):378–385.
   PubMed Web of Science ®Google Scholar
• Hamilton JB. Male pattern hair loss in man: types and incidence. Ann N Y Acad Sci. 1951;53:708–728.
   PubMed Web of Science ®Google Scholar
• Khumalo NP, Jessop S, Gumedze F, et al. Hairdressing and the prevalence of scalp disease in African adults. Epidemiol Heal Serv Res. 2007;157:981–988.
   Google Scholar
• Blumeyer A, Tosti A, Messenger A, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Ger Soc Dermatology. 2011;9:1–57.
   Google Scholar
• Lee WS, Lee HJ, Choi GS, et al. Guidelines for management of androgenetic alopecia based on BASP classification - The Asian Consensus Committee guideline. J Eur Acad Dermatolgy Venereol. 2013;27:1026–1034.
   PubMed Web of Science ®Google Scholar
• Kelly Y, Blanco A, Tosti A. Androgenetic Alopecia: An update of treatment options. Drugs. 2016 Sep;76:1349–1364.
   PubMed Web of Science ®Google Scholar
• Mirzoyev SA, Schrum AG, Davis MDP, et al. Lifetime incidence risk of Alopecia Areata estimated at 2.1 percent by rochester epidemiology project, 1990-2009. J Invest Dermatol. 2014;134(4):1141–1142.
   PubMed Web of Science ®Google Scholar
• Messenger AG, McKillop J, Farrant P, et al. British Association of Dermatologists’ guidelines for the management of alopecia areata 2012. Br J Dermatol. 2012;166:916–926.
   PubMed Web of Science ®Google Scholar
• Vázquez-Herrera NE, Tosti A. Current and future pharmacotherapy for alopecia areata. Expert Opinion on Orphan Drugs. 2015;3(4):419–431.
   Web of Science ®Google Scholar
• Mackay-Wiggan J, Jabbari A, Nguyen N, et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight. 2016;1(15):e89790.
   PubMed Web of Science ®Google Scholar
• Kennedy Crispin M, Ko JM, Craiglow BG, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016;1(15):e89776.
   PubMed Web of Science ®Google Scholar
• Trüeb RM. Chemotherapy-induced alopecia. Semin Cutan Med Surg. 2009;28(1):11–14.
   PubMed Web of Science ®Google Scholar
• Komen MM, Smorenburg CH, Van Den Hurk CJ, et al. Factors influencing the effectiveness of scalp cooling in the prevention of chemotherapy-induced alopecia. Oncologist. 2013;18(7):885–891.
   PubMed Web of Science ®Google Scholar
• Duvic M, Lemak NA, Valero V, et al. A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol. 1996;35(1):74–78.
   PubMed Web of Science ®Google Scholar
• Price VH. Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. J Am Acad Dermatol. 1987;16(3 Pt 2):730–736.
   PubMed Web of Science ®Google Scholar
• Fiedler-Weiss VC. Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata. J Am Acad Dermatol. 1987;16(3 Pt 2):745–748.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Charrete A. Topical minoxidil: systematic review and meta-analysis of its efficacy in androgenetic alopecia. Skinmed. 2015;13(3):185–189.
   PubMedGoogle Scholar
• Lutz G. Effects of Cyclosporin A on Hair. Skin Pharmacol. 1994;7:101–104.
   PubMedGoogle Scholar
• Gilhar A, Pillar T, Etzioni A. Topical cyclosporin A in alopecia areata. Acta Derm Venereol. 1989;69(3):252–253.
   PubMed Web of Science ®Google Scholar
• Gilhar A, Pillar T, Etzioni A. Topical cyclosporine in male pattern alopecia. J Am Acad Dermatol. 1990;22(2 Pt 1):251–253.
   PubMed Web of Science ®Google Scholar
• Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 1997;124(4):544–547.
   PubMed Web of Science ®Google Scholar
• Eisenberg DL, Toris CB, Camras CB. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. Surv Ophthalmol. 2002;47(1):105–115.
   Web of Science ®Google Scholar
• Blume-Peytavi U, Lönnfors S, Hillmann K, et al. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol. 2012;66(5):794–800.
   PubMed Web of Science ®Google Scholar
• Coronel-Pérez IM, Rodríguez-Rey EM, Camacho-Martínez FM. Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis. J Eur Acad Dermatol Venereol. 2010;24(4):481–485.
   PubMed Web of Science ®Google Scholar
• O’Donoghue MN. Eye cosmetics. Dermatol Clin. 2000;18(4):633–639.
   PubMed Web of Science ®Google Scholar
• Choy I, Lin S. Eyelash enhancement properties of topical dechloro ethylcloprostenolamide. J Cosmet Laser Ther. 2008;10(2):110–113.
   PubMed Web of Science ®Google Scholar
• Folligen cream. [ cited 2016 Aug 15]. Available at: http://store.reverseskinaging.com/Folligen_p/40.htm
   Google Scholar
• Shanmugam S, Wilkinson M. Allergic contact dermatitis caused by a cyanoacrylate-containing false eyelash glue. Contact Dermatitis. 2012;67(5):309–310.
   PubMed Web of Science ®Google Scholar
• Khanna M. Hair transplantation surgery. Indian J Plast Surg. 2008;41(l):56–63.
   Google Scholar
• Umar S. Eyelash transplantation using leg hair by follicular unit extraction. Plast Reconstr Surg Glob Open. 2015;3(3):e324.
   PubMedGoogle Scholar
• Epstein J. Facial hair restoration: hair transplantation to eyebrows, beard, sideburns, and eyelashes. Facial Plast Surg Clin N Am. 2013;21(3):457–467.
   PubMed Web of Science ®Google Scholar
• Woodward DF, Krauss AH, Chen J, et al. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol. 2001;45(4):337–345.
   Web of Science ®Google Scholar
• Lumigan label-FDA. [ cited 2016 June 20]. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022184s001lbl.pdf
   Google Scholar
• LATISSE® Prescribing Information – Allergan. [ cited 2016 June 20] Available at: http://www.allergan.com/assets/pdf/latisse_pi.pdf
   Google Scholar
• Woodward DF, Liang Y, Krauss AH. Prostamides (prostaglandin-ethanolamides) and their pharmacology. ‎Br. J. Pharmacol. 2008;153(3):410–419.
   PubMed Web of Science ®Google Scholar
• Krauss AH, Woodward DF. Update on the mechanism of action of bimatoprost: a review and discussion of new evidence. Surv Ophthalmol. 2004;49(1):5–11.
   Web of Science ®Google Scholar
• Woodward DF, Wang JW, Poloso NJ. Recent progress in prostaglandin F2α ethanolamide (prostamide F2α) research and therapeutics. Pharmacol Rev. 2013;65(4):1135–1147.
   PubMed Web of Science ®Google Scholar
• Tauchi M, Fuchs TA, Kellenberger AJ, et al. Characterization of an in vivo model for the study of eyelash biology and trichomegaly: mouse eyelash morphology, development, growth cycle, and anagen prolongation by bimatoprost. Br J Dermatol. 2010;162(6):1186–1197.
   PubMed Web of Science ®Google Scholar
• Tang-Liu DD, Cherukury M, Acheampong A, et al. Systemic Pharmacokinetics of Bimatoprost 0.03% Solution Following Once Daily Ocular Dosing In Normal, Healthy Subjects. Invest Ophthalmol Vis Sci. 2002;43(13):1085.
   Google Scholar
• FDA Briefing Document Dermatologic and Ophthalmic Drugs Advisory Committee Briefing Document. [ cited 2016 June 20]. Available at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DermatologicandOphthalmicDrugsAdvisoryCommittee/UCM511357.pdf
   Google Scholar
• Law SK. Bimatoprost in the treatment of eyelash hypotrichosis. Clin Ophthalmol. 2010;4:349–358.
   PubMedGoogle Scholar
• Hesketh PJ, Batchelor D, Golant M, et al. Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer. 2004;12(8):543–549.
   PubMed Web of Science ®Google Scholar
• Smith S, Fagien S, Whitcup SM, et al. Eyelash growth in subjects treated with bimatoprost: A multicenter, randomized, double-masked, vehicle-controlled, parallel-group study. J Am Acad Dermatol. 2012;66(5):801–806.
   PubMed Web of Science ®Google Scholar
• Fagien S, Walt JG, Carruthers J, et al. Patient-reported outcomes of bimatoprost for eyelash growth: results from a randomized, double-masked, vehicle-controlled, parallel-group study. ‎Aesthet Surg J. 2013;33(6):789–798.
   PubMed Web of Science ®Google Scholar
• Harii K, Arase S, Tsuboi R, et al. Bimatoprost for eyelash growth in Japanese subjects: two multicenter controlled studies. Aesth Plast Surg. 2014;38(2):451–460.
   PubMed Web of Science ®Google Scholar
• Ahluwalia GS. Safety and efficacy of bimatoprost solution 0.03% topical application in patients with chemotherapy-induced eyelash loss. J Investig Dermatol Symp Proc. 2013;16(1):73–76.
   PubMedGoogle Scholar
• Borchert M, Bruce S, Wirta D, et al. An evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects. Clin. Ophthalmol. 2016;10:419–429.
   PubMed Web of Science ®Google Scholar
• University of California, San Francisco. Efficacy study of latanoprost and bimatoprost solutions in promoting eyelash growth in patients with alopecia areata. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. [cited 2016 Jun 25]. Available at: https://clinicaltrials.gov/ct2/show/NCT00187577 NLM Identifier: NCT00187577.
   Google Scholar
• Vila TO, Camacho Martínez FM. Bimatoprost in the treatment of eyelash universalis alopecia areata. Int J Trichology. 2010;2(2):86–88.
   PubMedGoogle Scholar
• Wester ST, Lee WW, Shi W. Eyelash growth from application of bimatoprost in gel suspension to the base of the eyelashes. Ophthalmol. 2010;117(5):1024–1031.
   PubMed Web of Science ®Google Scholar
• Woodward JA, Haggerty CJ, Stinnett SS, et al. Bimatoprost 0.03% gel for cosmetic eyelash growth and enhancement. J Cosmet Dermatol. 2010;9(2):96–102.
   PubMed Web of Science ®Google Scholar
• Morris CL, Stinnett SS, Woodward JA. The role of bimatoprost eyelash gel in chemotherapy-induced madarosis: an analysis of efficacy and safety. Int J Trichology. 2011;3(2):84–91.
   PubMedGoogle Scholar
• Beer KR, Julius H, Dunn M, et al. Treatment of eyebrow hypotrichosis using bimatoprost: a randomized, double-blind, vehicle-controlled pilot study. Dermatol Surg. 2013;39(7):1079–1087.
   PubMed Web of Science ®Google Scholar
• Carruthers J, Beer K, Carruthers A, et al. Bimatoprost 0.03% for the treatment of eyebrow hypotrichosis. Dermatol Surg. 2016;42(5):608–617.
   PubMed Web of Science ®Google Scholar
• Zaher H, Gawdat H, Hegazy RA, et al. Bimatoprost versus mometasone furoate in the treatment of scalp alopecia areata: A pilot study. Dermatology. 2015;230(4):308–313.
   PubMed Web of Science ®Google Scholar
• Duke University. Topical bimatoprost effect on androgen dependent hair follicles. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. [cited 2016 Aug 25]. Available at: https://clinicaltrials.gov/ct2/show/NCT02170662 NLM Identifier: NCT02170662.
   Google Scholar
• Allergan. Safety and efficacy study of bimatoprost in the treatment of men with androgenic alopecia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. [cited 2016 Aug 25]. Available at: https://clinicaltrials.gov/ct2/show/NCT01325337 NLM Identifier: NCT01325337.
   Google Scholar
• Allergan. A safety and efficacy study of bimatoprost in men with Androgenic Alopecia (AGA). In. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. [cited 2016 Aug 25]. Available at: https://clinicaltrials.gov/ct2/show/NCT01904721 NLM Identifier: NCT01904721.
   Google Scholar
• Allergan. Safety and efficacy study of bimatoprost in the treatment of women with female pattern hair loss. In. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. [cited 2016 Aug 25]. Available at: https://clinicaltrials.gov/ct2/show/NCT01325350 NLM Identifier: NCT01325350.
   Google Scholar
• Wirta D, Pariser DM, Steven G, et al. Bimatoprost 0.03% for the treatment of eyelash hypotrichosis a pooled safety analysis of six randomized, double-masked clinical trials. J Clin Aesthet Dermatol. 2015;8(7):17–29.
   PubMedGoogle Scholar